Nipah Vaccine: Oxford-Developed Shot Shows Promise in Trials

A Phase 1 clinical trial of the ChAdOx1 NipahB vaccine, developed by the University of Oxford, has shown it to be safe and capable of generating an immune response. This development is crucial as Nipah virus, a highly lethal pathogen, continues to cause outbreaks in countries like India and Bangladesh.

• Oxford's ChAdOx1 NipahB vaccine successfully completed Phase 1 trial.
• Study published in The Lancet confirms vaccine safety and immune response.
• Nipah virus remains a high-priority pathogen with pandemic potential.
• Ongoing outbreaks in India highlight urgent need for effective vaccines.
• Serum Institute of India involved in manufacturing for further trials.
• Phase 2 trials have recently commenced in Bangladesh for the vaccine.

Read the full story on Quick Digest.